All Stories

  1. High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas
  2. Tatton-Brown-Rahman syndrome: A new multiple endocrine neoplasia syndrome with intellectual disability?
  3. Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant
  4. Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus
  5. The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism
  6. Pituitary Acrogigantism: From the Past to the Future
  7. The Role of MCM9 in the Etiology of Sertoli Cell-Only Syndrome and Premature Ovarian Insufficiency
  8. Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion
  9. Bases moléculaires du gigantisme hypophysaire
  10. Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases
  11. Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma
  12. Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism
  13. Comment on "Persistent remission of acromegaly in a patient with GH‐secreting pituitary adenoma: Effect of treatment with pasireotide long‐acting release and consequence of treatment withdrawal"
  14. Dutch founder SDHB exon 3 deletion in patients with pheochromocytoma-paraganglioma in South Africa
  15. Genetics of Pituitary Adenoma Syndromes
  16. A hard look at cardiac safety with dopamine agonists in endocrinology
  17. Differentiated thyroid carcinoma in sporadic and familial presentations of acromegaly: A case series
  18. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11
  19. miR ‐34a is upregulated in AIP ‐ mutated somatotropinomas and promotes octreotide resistance
  20. The Epidemiology of Pituitary Adenomas
  21. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis
  22. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA)
  23. Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview
  24. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
  25. Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion
  26. The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study
  27. Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas
  28. Acromegaly in the setting of Tatton-Brown-Rahman Syndrome
  29. Long-term remission of disseminated parathyroid cancer following immunotherapy
  30. GENETICS IN ENDOCRINOLOGY: Somatic and germline mutations in the pathogenesis of pituitary adenomas
  31. Compound heterozygous mutations in the luteinizing hormone receptor signal peptide causing 46,XY disorder of sex development
  32. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
  33. Shrinkage of pituitary adenomas with pasireotide
  34. AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center
  35. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
  36. Epidemiology and Management Challenges in Prolactinomas
  37. Genetic Testing in Pituitary Adenomas: What, How, and In Whom?
  38. The causes and consequences of pituitary gigantism
  39. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant
  40. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors
  41. MAX intragenic deletions occur in patients with pheochromocytoma and pituitary adenoma
  42. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats
  43. Acromegaly characteristics at diagnosis: the largest study to date.
  44. Adipsic diabetes insipidus revealing a bifocal intracranial germinoma
  45. AIP mutations and gigantism
  46. Overview of XLAG and how we discovered it
  47. Transdifferentiation of Neuroendocrine Cells
  48. Elucidating the molecular mechanisms underlying AIP dependent tumorigenesis
  49. GPR101 orphan receptor: a novel cause of growth hormone deregulation
  50. Comment on “Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene”
  51. Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly
  52. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
  53. New technology combined with a new disease used to explain an old case of gigantism
  54. Genetics of Pituitary Tumor Syndromes
  55. The role of AIP mutations in pituitary adenomas: 10 years on
  56. Erratum to: Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia
  57. Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma
  58. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia
  59. A region, common to all glycoprotein homones, essential for secretion
  60. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
  61. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening
  62. Characterization ofGPR101transcript structure and expression patterns
  63. Genetic predisposition to breast cancer occurring in a male-to-female transsexual patient
  64. Combined treatment with octreotide LAR and pegvisomant in patients with gigantism - acromegaly: clinical evaluation and genetic screening
  65. Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells
  66. MANAGEMENT OF ENDOCRINE DISEASE: Pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis
  67. Genetic risk of breast cancer is important to consider in transexuals receiving hormone therapy
  68. Screening for GPR101 defects in pediatric pituitary corticotropinomas
  69. Mosaicism for X chromosome duplications including GPR101 cause X-LAG syndrome in sporadic males
  70. Gigantism, acromegaly and GPR101
  71. Bifocal intracranial germinoma presenting as adipsic diabetes insipidus
  72. Erratum to “Pituitary gigantism: Causes and clinical characteristics” [Ann. Endocrinol. (Paris) 76 (2015) 643–649]
  73. GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency
  74. Functioning Pituitary Adenomas
  75. List of Contributors
  76. Growth hormone releasing hormone is abnormally elevated in patients with X-linked acrogigantism
  77. Pituitary gigantism: Causes and clinical characteristics
  78. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome
  79. Étude moléculaire du gène AIP sur plus de 1400 individus atteints d’adénome hypophysaire
  80. Hyperparathyroïdie primaire familiale isolée – corrélation génotype-phénotype des mutations MEN1 ?
  81. Une forme compliquée d’hypercalcémie hypocalciurique familiale
  82. Causes and Characteristics of Pituitary Gigantism
  83. Pancreatitis in familial hypocalciuric hypercalcaemia
  84. Molecular analysis of miRNA expression profiles in AIP mutation positive somatotropinomas
  85. Recurrence of GH-secreting pituitary adenomas during puberty in children with germline AIP mutations: a clinical challenge
  86. Molecular and pathological determinants of somatostatin analogue resistance: somatotropinomas in AIP mutated and X-LAG syndrome patients
  87. The genetic causes of pituitary gigantism
  88. The clinical characteristics of X-linked acro-gigantism syndrome
  89. X-linked acro-gigantism (X-LAG): a new form of infant-onset pituitary gigantism
  90. Gigantism, Acromegaly, and GPR101 Mutations
  91. A novel inactivating mutation of the LH/chorionic gonadotrophin receptor with impaired membrane trafficking leading to Leydig cell hypoplasia type 1
  92. Familial Isolated Pituitary Adenomas (FIPA) and Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene
  93. X-linked acrogigantism syndrome: clinical profile and therapeutic responses
  94. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences
  95. Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation
  96. McCune-Albright Syndrome: A Detailed Pathological and Genetic Analysis of Disease Effects in an Adult Patient
  97. Le cancer thyroïdien papillaire familial (FNMTC) : études cliniques et génétiques chez 8 familles
  98. Intérêt du signal T2 des adénomes hypophysaires à GH traités par analogues de la somatostatine – premiers résultats de l’étude IRMA#2
  99. Challenges and controversies in the treatment of prolactinomas
  100. A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma
  101. A bittersweet symphony
  102. Surgical management of pituitary adenomas
  103. The Third/Second Generation PTH Assay Ratio as a Marker for Parathyroid Carcinoma: Evaluation Using an Automated Platform
  104. Deletion of exons 1–3 of the MEN1 gene in a large Italian family causes the loss of menin expression
  105. Coexistence entre adénome hypophysaire et phéochromocytome – présentation de cas
  106. FIPA : étude clinique et génétique à l’Hôpital « King Edward Memorial », Bombay (Mumbai), Inde
  107. Le Gigantisme : les résultats d’une étude clinique et génétique internationale
  108. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations
  109. Faculty Opinions recommendation of Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma.
  110. Receptor expression in craniopharyngiomas causing tumor growth in pregnancy: case report and review of the literature
  111. Characteristics of patients with pituitary gigantism: results of an international study
  112. Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene
  113. Young patients with pituitary adenomas should be assessed for MEN1 and AIP mutations
  114. Familial Pituitary Adenomas: An Overview
  115. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
  116. Faculty Opinions recommendation of Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.
  117. Faculty Opinions recommendation of Should aip gene screening be recommended in family members of FIPA patients with R16H variant?
  118. A study of the characteristics of cabergoline-resistant prolactinomas
  119. The Liege Acromegaly Survey (LAS): A new software tool for the study of acromegaly
  120. Clinical and genetic aspects of familial isolated pituitary adenomas
  121. Faculty Opinions recommendation of The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression.
  122. Overview of genetic testing in patients with pituitary adenomas
  123. Clinical characterization of cabergoline resistant prolactinomas: A multicenter experience on 92 patients
  124. A prospective study of cardiac valvular status in patients treated with cabergoline for endocrine disease
  125. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds
  126. Faculty Opinions recommendation of Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.
  127. Faculty Opinions recommendation of Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain.
  128. 36. A Tall Man with Hypogonadism
  129. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas
  130. Familial Pituitary Tumor Syndromes
  131. What to do with a pituitary incidentaloma?
  132. A Novel AIP Mutation Related to Familial Isolated Pituitary Adenomas (FIPA)
  133. Strategies for Screening and Management of Familial Isolated Pituitary Adenomas (FIPA): Our Experience on 17 Families in a Single Center in Brazil
  134. Impact of Germline AIP Mutations on Tumor Characteristics and Management in Young Acromegalic Patients: Results of an Age- and Tumor-Diameter-Matched Cohort Study
  135. Mutations of calcium-sensing receptor gene: two novel mutations and overview of impact on calcium homeostasis
  136. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation
  137. Resistant prolactinomas
  138. Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications
  139. Genetic Causes of Familial Pituitary Adenomas
  140. Familial pituitary adenomas
  141. Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene
  142. Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study
  143. The Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma
  144. Management of acromegaly
  145. The genetics of pituitary adenomas
  146. Hyperplasia-Adenoma Sequence in Pituitary Tumorigenesis Related to AIP Mutation.
  147. Prevalence of double pituitary adenomas in a surgical series: Clinical, histological and genetic features
  148. The role of germlineAIP,MEN1, PRKAR1A,CDKN1BandCDKN2Cmutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes
  149. Functioning Pituitary Adenomas
  150. Genetics of Cushing’s Syndrome
  151. Contributors
  152. Genetic Factors in the Development of Pituitary Adenomas
  153. Pituitary adenomas in young patients: when should we consider a genetic predisposition?
  154. The epidemiology and genetics of pituitary adenomas
  155. De la génétique des adénomes hypophysaires familiaux
  156. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene
  157. Mutaciones de AIP en adenomas hipofisarios familiares y esporádicos: experiencia local y revisión de la literatura
  158. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly
  159. Familial pituitary adenomas
  160. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications
  161. Genetic, Molecular and Clinical Features of Familial Isolated Pituitary Adenomas
  162. Adénomes hypophysaires familiaux
  163. Update on Familial Pituitary Tumors: from Multiple Endocrine Neoplasia Type 1 to Familial Isolated Pituitary Adenoma
  164. Testicular Effects of Isolated Luteinizing Hormone Deficiency and Reversal by Long-Term Human Chorionic Gonadotropin Treatment
  165. Central Nervous System-Acting Drugs Influencing Hypothalamic-Pituitary-Adrenal Axis Function
  166. UPDATE ON THE TREATMENT OF PITUITARY ADENOMAS: FAMILIAL AND GENETIC CONSIDERATIONS
  167. Toll‐like receptor‐4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel
  168. Cabergoline and the risk of valvular lesions in endocrine disease.
  169. Absence of hypogonadism in a male patient with a giant prolactinoma: A clinical paradox
  170. Current and future perspectives on recombinant growth hormone for the treatment of obesity
  171. Pseudomalabsorption of thyroid hormones: case report and review of the literature
  172. Characteristics of familial isolated pituitary adenomas
  173. Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma
  174. The clinical, pathological, and genetic features of familial isolated pituitary adenomas
  175. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene
  176. Mutations in theAryl Hydrocarbon Receptor Interacting ProteinGene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas
  177. Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families
  178. The Epidemiology and Management of Pituitary Incidentalomas
  179. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
  180. P1-046 - The liege acromegaly survey
  181. CO05 - Identification d’une famille porteuse d’une nouvelle mutation bêta-LH accompagnée d’hypogonadisme
  182. P2-085 - Endocrine abnormalities in MC Cune-Albright syndrome
  183. P1-044 - Les patients acromégales sont-ils mal pris en charge ? de la mauvaise utilisation des bases de données
  184. The original clinical description of familial isolated pituitary adenomas (FIPA)
  185. Serum levels of soluble CD163 correlate with the inflammatory process in coeliac disease
  186. Desloratadine for allergic rhinitis
  187. Diagnostic characteristics and therapeutic responses in acromegaly: The liege acromegaly survey
  188. Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?
  189. Somatostatin Analogs in the Gastrointestinal Tract
  190. Predictors and rates of treatment-resistant tumor growth in acromegaly
  191. Acromegaly
  192. Clinical and Genetic Features of Familial Pituitary Adenomas
  193. Treatment of Pituitary Tumors: Somatostatin
  194. The Epidemiology of Prolactinomas
  195. Cytokine Dysregulation, Inflammation and Well-Being
  196. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
  197. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique
  198. Hypogonadism in a Patient with a Mutation in the Luteinizing Hormone Beta-Subunit Gene
  199. P018 - Une approche de la vraie prévalence des tumeurs hypophysaires
  200. CO10 - La réduction chirurgicale de la masse tumorale des adenomas hypophysaires améliore le contrôle médical de l’acromégalie par les analogues de la somatostatine
  201. Oral vitamin C reduces the injury to skeletal muscle caused by compartment syndrome
  202. Hormonal and Biochemical Normalization and Tumor Shrinkage Induced by Anti-Parathyroid Hormone Immunotherapy in a Patient with Metastatic Parathyroid Carcinoma
  203. Lanreotide Autogel?? for Acromegaly
  204. Gonadotropin-Secreting Tumors
  205. Oral vitamin C attenuates acute ischaemia-reperfusion injury in skeletal muscle
  206. Alcoholic ketoacidosis presenting as diabetic ketoacidosis
  207. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines☆☆☆★
  208. Pathologie inflammatoire de ľhypophyse et grossesse